Radiotherapy Market Size, Share, Growth, and Industry Analysis, By Type (External Beam Radiotherapy,Internal Beam Radiotherapy,Systemic Radiotherapy,Others), By Application (Hospitals,Cancer Research Institutes,Ambulatory & Radiotherapy Centers,Others), Regional Insights and Forecast to 2035

Radiotherapy Market Overview

The global Radiotherapy Market size is projected to grow from USD 7403.96 million in 2026 to USD 7680.87 million in 2027, reaching USD 10304.8 million by 2035, expanding at a CAGR of 3.74% during the forecast period.

The global Radiotherapy Market encompasses technologies and systems used in cancer treatment via ionizing radiation, including external beam therapy, internal beam (brachytherapy), systemic radiotherapy, and associated planning and quality assurance tools. As of recent estimates, over 14,000 radiotherapy installations exist globally, servicing more than 4 million treatment courses annually. In many regions, over 60 % of oncology centers deploy advanced linear accelerators with image-guided capabilities. The Radiotherapy Market Report and Radiotherapy Market Insights highlight that over 80 % of cancer types are treated via radiotherapy at some stage, making radiotherapy a foundational pillar in oncological care.

The USA Radiotherapy Market is among the most mature globally. As of a recent industry estimate, the U.S. hosts over 2,800 radiotherapy treatment centers and deploys more than 4,500 active linear accelerators across hospitals and cancer centers. In recent years, over 1 million radiotherapy treatment sessions were delivered annually in the U.S. The Radiotherapy Industry Analysis indicates that approximately 55 % of all oncology patients in the U.S. receive radiation therapy over the course of treatment. In surveys, more than 70 % of U.S. radiotherapy centers have adopted image-guided or stereotactic systems.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 65 % of radiotherapy buyers cite increasing cancer incidence as the primary motivator
• Major Market Restraint: 30 % of prospective purchasers indicate prohibitive capital cost as barrier
• Emerging Trends: 45 % of new orders include AI-guided planning modules
• Regional Leadership: North America accounts for 38 % to 42 % of global installed base
• Competitive Landscape: Top 10 vendors supply over 70 % of global installations
• Market Segmentation: External beam type comprises ~60 % share of procedures
• Recent Development: 25 % of suppliers launched MR-Linac or adaptive radiotherapy systems in past 3 years

Radiotherapy Market Latest Trends

The Radiotherapy Market Trends today show rapid adoption of adaptive radiotherapy: in 2024, 28 % of new external beam orders included adaptive features. Integration of AI in contouring and dose planning has increased, with 35 % of oncology centers reporting use of AI modules in 2024. The Radiotherapy Market Research shows that image guidance techniques now accompany 75 % of treatment plans in developed regions. Proton therapy adoption continues, with at least 120 proton therapy centers active worldwide and over 15 under construction. Use of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) now constitutes around 12 % of radiotherapy treatments. 

Radiotherapy Market Dynamics

DRIVER

"Rising global cancer burden and aging population"

In recent years, the incidence of cancer has crossed 20 million new cases annually, increasing demand for radiotherapy systems. In many countries, cancer prevalence has grown by over 25 % in the past decade, pushing new radiotherapy facility buildouts. The Radiotherapy Market Growth is strongly tied to increasing detection of tumors, especially breast, lung, and colorectal cancers which together account for upwards of 40 % of radiotherapy cases.

RESTRAINT

"High upfront cost, infrastructure, and regulatory hurdles"

Acquisition of advanced radiotherapy systems (e.g. MR-Linac, proton facilities) requires tens of millions in capital outlay and heavy shielding infrastructure. Many facilities report installation lead times of 12 to 24 months. In surveys, about 30 % of hospitals cite regulatory certification and licensing delays as cause of project delays. Additionally, 40 % of buyers mention maintenance, service, and software upgrade costs as deterrents. Complex local radiation safety and compliance rules in many jurisdictions impose further setup costs equivalent to 15–25 % of equipment costs.

OPPORTUNITIES

"Expansion into underserved regions and next-gen modalities"

Many countries in Asia, Africa, and Latin America have radiotherapy coverage of less than 50 % of cancer patient demand, offering a quantifiable expansion opportunity. In Africa, fewer than 10 countries currently maintain a national radiotherapy program. Some governments plan to install 200+ new radiotherapy units over the next decade. Another opportunity lies in next-gen modalities: proton therapy adoption is still less than 5 % of global radiotherapy capacity, suggesting space for growth. Hybrid systems combining MR and linac are only installed in fewer than 50 centers globally today.

CHALLENGES

"Skilled workforce shortage and reimbursement complexity"

Operating advanced radiotherapy systems requires medical physicists, dosimetrists, radiation oncologists, and radiotherapy technologists. Many nations report training capacity deficits: in a recent survey, 35 % of cancer centers cited inability to hire or retain medical physicists. Over 20 % of new radiotherapy machines remain idle due to missing staff. In addition, complexities in reimbursement and payer approval cause delays: in multiple countries, 25 % of radiotherapy claims are rejected or delayed due to coding or coverage issues.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Radiotherapy Market Segmentation

BY TYPE

External Beam Radiotherapy (EBRT): dominates the radiotherapy procedure volume, accounting for approximately 60 % to 65 % of all radiotherapy treatments. Within EBRT, modalities such as IMRT, VMAT, image-guided RT, and stereotactic radiotherapy comprise more than 70 % of new installations. Many radiotherapy centers perform over 20,000 EBRT fractions annually per linac machine. The Radiotherapy Market Report notes that over 4,000 new EBRT units were installed globally in the last decade.

The External Beam Radiotherapy segment is projected to command a market size of about USD 4,282.22 million in 2025 (approximately 60 % share)

Top 5 Major Dominant Countries in the External Beam Radiotherapy Segment

• The United States accounts for roughly USD 1,369.33 million in the External Beam Radiotherapy segment, holding a share near 32 % and experiencing the same growth rate base.
• Germany contributes an estimated USD 512.66 million in this segment, representing about 12 % share in External Beam Radiotherapy under the model.
• Japan holds approximately USD 425.02 million in the External Beam Radiotherapy share, or about 10 % segment share.
• China’s External Beam Radiotherapy share is estimated near USD 341.33 million, about 8 % of the segment under the forecast model.
• United Kingdom secures around USD 256.11 million in External Beam Radiotherapy, corresponding to ~6 % share of that segment.

Internal Beam Radiotherapy: Internal Beam Radiotherapy, or brachytherapy, contributes roughly 20 % to 25 % of radiotherapy treatments globally. It includes high-dose rate (HDR) and low-dose rate (LDR) modalities. Over 700 centers globally have HDR brachytherapy installations, often in gynecologic, prostate, and breast cancer pods. In many developed markets, 30 % of cervical cancer patients receive brachytherapy bows.

The Internal Beam Radiotherapy (brachytherapy and related) segment is forecasted to reach approximately USD 1,427.41 million in 2025, making up about 20 % share.

Top 5 Major Dominant Countries in the Internal Beam Radiotherapy Segment

• The United States leads with an estimated USD 428.22 million in Internal Beam Radiotherapy, capturing nearly 30 % share of that sub-segment.
• Germany contributes about USD 171.01 million, representing ~12 % segment share in Internal Beam Radiotherapy.
• Japan’s share in this type is estimated at USD 142.74 million, ~10 % of the type’s share.
• India registers roughly USD 114.19 million in Internal Beam Radiotherapy under the model (8 % share).
• United Kingdom holds around USD 85.64 million in Internal Beam Radiotherapy, ~6 % of that type.

Systemic Radiotherapy: Systemic Radiotherapy relies on radiopharmaceuticals (e.g. I-131, Lu-177, Radium-223) and accounts for about 10 % to 15 % of radiation therapy use. In recent years, over 1,000 radiopharmaceutical therapy centers globally administer radionuclide therapies as part of systemic radiotherapy. For example, over 25,000 Lu-177 therapies were delivered in 2023 alone worldwide. It is especially used in thyroid cancer, neuroendocrine tumors, and bone metastases.

The Systemic Radiotherapy segment, involving radiopharmaceuticals and systemic radiation treatment, is estimated at about USD 1,070.55 million in 2025.

Top 5 Major Dominant Countries in the Systemic Radiotherapy Segment

• The United States leads this segment with approximately USD 321.17 million in Systemic Radiotherapy, capturing ~30 % of that sub-market.
• Germany contributes about USD 128.58 million, representing ~12 % share of that segment.
• Japan’s share in systemic radiotherapy is estimated at USD 107.06 million, ~10 %.
• France is projected at USD 85.64 million in Systemic Radiotherapy, ~8 % share.
• China’s share is modeled at USD 85.64 million, ~8 % of Systemic Radiotherapy.

Others: The “Others” category covers emerging modalities such as intraoperative radiotherapy (IORT), radioisotope-seed implants outside traditional brachytherapy, and emerging device innovations. This segment is small—less than 5 % of total radiotherapy procedures globally—but growing. Over 150 IORT systems are installed in specialized cancer centers worldwide. Some mobile radiotherapy units and portable X-ray therapy machines fall and expand within this “Others” group. The Radiotherapy Market Analysis sees this as a niche growth segment over the next decade.

The “Others” radiotherapy types (e.g. intraoperative, novel hybrids) are expected to represent about USD 356.85 million in 2025, making up around 5 % share of the Radiotherapy market under your valuation.

Top 5 Major Dominant Countries in the Others Segment

• The United States is estimated to hold USD 107.06 million in the Others segment, about 30 % of that niche sub-market.
• Germany contributes approximately USD 42.83 million, ~12 % share of Others.
• Japan holds roughly USD 35.69 million, ~10 % share in Others.
• United Kingdom’s share in Others is near USD 28.55 million, ~8 % of the Others segment.
• India accounts for around USD 21.41 million in Others, ~6 % share of that niche.

BY APPLICATION

Hospitals:  the primary end-user in the Radiotherapy Market, accounting for roughly 50 % to 60 % of installed radiotherapy capacity. Most major cancer centers, academic hospitals, and tertiary hospitals include in-house radiotherapy departments. In countries like the U.S., over 80 % of radiotherapy procedures are performed in hospitals. Many hospitals deliver more than 50,000 fractions annually, with multiple linac suites.

The Hospitals application segment within the Radiotherapy Market is projected to reach approximately USD 4,282.22 million in 2025, representing 60 % of the total market share, and is expected to maintain consistent growth aligned with the 3.74 % forecast trend.

Top 5 Major Dominant Countries in the Hospitals Application

• The United States leads hospital-based radiotherapy with an estimated USD 1,369.33 million in market size, accounting for roughly 32 % of this application segment and expanding steadily under the projected 3.74 % growth rate.
• Germany contributes approximately USD 512.66 million to the Hospitals application, holding nearly 12 % of the segment share and reflecting robust growth potential driven by increased installations of advanced radiotherapy systems.
• Japan commands about USD 425.02 million in hospital radiotherapy value, equating to 10 % of the global hospital segment, driven by strong technological adoption across oncology and healthcare infrastructure.
• China holds an estimated USD 341.33 million market size within the hospital-based radiotherapy segment, representing 8 % of the share, supported by expanding healthcare investments and oncology program rollouts.
• The United Kingdom secures roughly USD 256.11 million in hospital radiotherapy, corresponding to about 6 % of this application, propelled by modernization of national cancer treatment networks and hospital upgrades.

Cancer Research Institutes: Cancer Research Institutes and oncology centers contribute to radiotherapy deployment, particularly in innovation, clinical trials, and advanced therapy adoption. They typically host novel systems, pilot projects, and early adoption of MR-Linacs and proton therapy. Though they account for a smaller share (10 % to 15 % of installations), they disproportionately deploy over 25 % of advanced modality machines.

The Cancer Research Institutes segment in the Radiotherapy Market is forecasted at approximately USD 1,070.55 million in 2025, accounting for 15 % of the total global share, as research facilities increasingly deploy radiotherapy equipment for clinical trials and technology validation.

Top 5 Major Dominant Countries in the Cancer Research Institutes Application

• The United States dominates radiotherapy use in Cancer Research Institutes with a market size of about USD 321.17 million, representing nearly 30 % of the segment share, supported by advanced cancer research and innovation clusters.
• Germany contributes approximately USD 128.58 million to the Cancer Research Institutes application, holding about 12 % share, fueled by its strong network of academic oncology institutions and collaborative research funding.
• Japan’s contribution to this segment stands at around USD 107.06 million, accounting for 10 % of the market share, reflecting consistent investment in cancer research and proton therapy centers.
• The United Kingdom records an estimated USD 85.64 million in radiotherapy market size within research institutes, equating to 8 % of the share, emphasizing translational oncology and radiological innovation programs.
• France secures around USD 85.64 million in this segment, contributing roughly 8 % share, driven by its high concentration of public and private cancer research facilities integrating advanced radiation systems.

Ambulatory & Radiotherapy Centers: Freestanding ambulatory radiotherapy centers (including cancer center satellites) make up about 20 % to 25 % of overall radiotherapy capacity in mature markets. Many deliver high-volume external beam therapy and supportive services. In markets such as the U.S., nearly 30 % of new linear accelerator orders go to non-hospital settings. These centers often deliver over 30,000 fractions per year. Their operational efficiency and lower overhead present a competitive slice of Radiotherapy Market Growth opportunity.

The Ambulatory & Radiotherapy Centers segment of the Radiotherapy Market is projected to achieve around USD 1,070.55 million in 2025, representing 15 % of the total market, reflecting strong adoption among independent and outpatient oncology service providers.

Top 5 Major Dominant Countries in the Ambulatory & Radiotherapy Centers Application

• The United States leads with a projected USD 321.17 million market size in Ambulatory & Radiotherapy Centers, capturing approximately 30 % of this segment, driven by the expansion of standalone cancer care facilities.
• Germany records approximately USD 128.58 million in this segment, holding 12 % of the share, supported by a growing network of independent outpatient radiation centers.
• Japan’s ambulatory radiotherapy market accounts for about USD 107.06 million, equivalent to 10 % of the segment, reflecting steady uptake across private oncology facilities.
• The United Kingdom contributes roughly USD 85.64 million to this application, around 8 % share, owing to decentralization of cancer care into specialized radiotherapy units.
• China represents approximately USD 85.64 million in ambulatory radiotherapy value, contributing 8 % share, driven by growing demand for outpatient and regional cancer treatment services.

Others: The “Others” application covers settings such as mobile clinics, rural outreach units, palliative care centers, and hybrid oncology units in community hospitals. Their share remains modest—around 5 % to 10 %—but their presence is expanding in underserved regions. Some hybrid oncology units in rural hospitals deliver up to 5,000 fractions per year. This application category offers Radiotherapy Market Opportunities for cost-optimized, compact radiotherapy solutions and outreach deployment.

The “Others” application segment within the Radiotherapy Market is valued at approximately USD 356.85 million in 2025, comprising 5 % of the total market share, and includes community-based centers, mobile clinics, and palliative radiotherapy programs.

Top 5 Major Dominant Countries in the Others Application

• The United States contributes around USD 107.06 million to the “Others” segment, representing 30 % of its share, with expanding demand for mobile and palliative radiotherapy solutions.
• Germany accounts for approximately USD 42.83 million within this application, equating to 12 % share, reflecting increased use of outreach and community oncology facilities.
• Japan holds about USD 35.69 million in market size within the “Others” category, representing 10 % share, supported by mobile radiotherapy deployment in rural hospitals.
• The United Kingdom’s radiotherapy market for “Others” applications stands at USD 28.55 million, corresponding to 8 % of this segment, focusing on community treatment integration programs.
• India contributes nearly USD 21.41 million to the “Others” segment, or 6 % of the market share, driven by oncology outreach expansion and low-cost radiotherapy installations.

Radiotherapy Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America remains the global leader in radiotherapy deployment, commanding approximately 38 % to 42 % of global installed bases. The region hosts over 7,000 radiotherapy systems, including more than 300 proton therapy suites and 30 MR-Linac installations. In the U.S. alone, over 2,800 radiotherapy treatment centers operate; Canada adds over 150 centers. In recent years, U.S. institutions have placed more than 500 new linac orders, and over 35 proton therapy beamlines are under development. North America also leads in advanced modality adoption: more than 25 MR-Linac systems and 40 adaptive radiotherapy suites are in active use.

The North America region is projected to lead the global Radiotherapy Market in 2025, with an estimated market size of approximately USD 2,855 million, accounting for about 40 % of total share, driven by high adoption of precision radiation systems.

North America – Major Dominant Countries in the Radiotherapy Market

• The United States holds an estimated USD 2,142 million market size, equivalent to roughly 30 % of global share, supported by over 2,800 treatment facilities and broad adoption of MR-Linac and proton systems nationwide.
• Canada’s Radiotherapy Market is valued at USD 214 million, representing 3 % of the total share, with more than 200 active treatment centers serving advanced IMRT and IGRT procedures.
• Mexico records approximately USD 143 million, or 2 % of the market share, as it expands oncology infrastructure with 50 new radiotherapy projects planned by 2030.
• Brazil (partially classified in the Americas cluster) achieves around USD 107 million in radiotherapy market value, driven by new installations in urban cancer hospitals.
• Colombia contributes USD 71 million, representing 1 % of the total market, focusing on increasing equipment density in regional treatment networks.

Europe

Europe’s Radiotherapy Market shares approximately 25 % to 30 % of global installed systems. Countries such as Germany, France, UK, Spain, and Italy host over 3,000 radiotherapy installations collectively. Germany alone maintains more than 500 linear accelerators, and France exceeds 400. The UK operates over 300 radiotherapy machines, often in integrated cancer centers. Europe has invested in over 15 proton therapy complexes, and about 20 MR-Linac systems in operation or planned. Many European nations mandate radiotherapy access with benchmarks of ~1 machine per 1 million population; countries such as the Netherlands and Sweden exceed those benchmarks.

Europe’s Radiotherapy Market is forecasted at approximately USD 1,998 million in 2025, capturing about 28 % of the global share, supported by advanced research facilities, government funding schemes, and extensive clinical infrastructure for radiation oncology.

Europe – Major Dominant Countries in the Radiotherapy Market

• Germany commands about USD 714 million in market size, holding 10 % of global share and operating over 500 active radiotherapy machines nationwide.
• The United Kingdom records approximately USD 500 million, representing 7 % of the global share, supported by 350 installations and centralized NHS oncology networks.
• France achieves around USD 429 million in market value, corresponding to 6 % share, with 450 modern treatment units distributed across its cancer centers.
• Italy holds an estimated USD 286 million share, equivalent to 4 % of the market, with new investments targeting southern regions for equipment expansion.
• Spain registers roughly USD 214 million in market value, about 3 % of the global share, reflecting rapid adoption of advanced external beam technologies.

Asia-Pacific

Asia-Pacific is the fastest growing radiotherapy region, with share estimates from 15 % to 20 %. Countries such as China, India, Japan, South Korea and Australia account for the majority of installations. China alone has over 2,000 linacs installed, and India has increased capacity by more than 200 units in the past five years. Japan and South Korea maintain high utilization with many centers exceeding 30,000 fractions yearly. Australia has more than 150 linacs serving dispersed populations. Several APAC countries are initiating proton therapy programs: China has 6 proton centers active, and India has commissioned at least one. Adaptive radiotherapy uptake in APAC is around 15 % of new installations.

Asia is expected to account for approximately USD 1,712 million of the global Radiotherapy Market in 2025, equating to roughly 24 % share, driven by expanding oncology capacity and rapid equipment modernization in China and India.

Asia – Major Dominant Countries in the Radiotherapy Market

• China leads the region with approximately USD 857 million in market size, equivalent to 12 % global share, operating over 2,000 radiotherapy installations and five proton centers.
• India’s radiotherapy market is valued near USD 571 million, around 8 % global share, with nearly 700 operational centers and rapid growth in tier-2 cities.
• Japan holds an estimated USD 429 million market value, roughly 6 % of global share, with advanced oncology hospitals and high equipment density.
• South Korea records USD 286 million, 4 % of the market, supported by strong government R&D and AI-driven therapy integration.
• Australia represents about USD 214 million, 3 % of the market, serving regional populations with more than 150 active radiotherapy systems.

Middle East & Africa

Middle East & Africa region is the most underpenetrated in radiotherapy, contributing only about 5 % to 8 % of global deployment. In the Middle East, countries like Saudi Arabia, UAE, Egypt, and Turkey host most advanced centers—each with dozens of linacs and a few proton or MR-Linac programs. For example, UAE has over 20 installed systems and recently launched its first MR-Linac. Saudi Arabia and Egypt each operate 40–60 linear accelerators. In Africa, South Africa, Nigeria, Kenya and Egypt dominate capacity: South Africa has ~30 linacs, Egypt ~25. Many African nations have no functional radiotherapy at all. More than 60 planned radiotherapy projects are reported across Africa and the Middle East in the next 5–8 years.

The Middle East and Africa region is forecasted to hold around USD 570 million of the global Radiotherapy Market in 2025, representing 8 % of the total share, driven by rising oncology investments and public-private healthcare partnerships.

Middle East & Africa – Major Dominant Countries in the Radiotherapy Market

• United Arab Emirates is valued at approximately USD 143 million, about 2 % of the global share, with multiple new cancer centers equipped with IMRT systems.
• Saudi Arabia accounts for around USD 114 million, nearly 1.6 % share, and plans to add 20 new oncology facilities within five years.
• South Africa represents USD 86 million, 1.2 % of the global market, serving as the continent’s most developed radiotherapy network.
• Egypt registers USD 71 million, 1 % share, expanding through public health investment in national cancer centers.
• Kenya is estimated at USD 57 million, 0.8 % share, with radiotherapy projects under construction in Nairobi and Mombasa.

List of Top Radiotherapy Companies

• Theragenics Corporation
• ProTom International, Inc
• Nordion, Inc
• Isoray Medical, Inc
• Mitsubishi Electric Corporation
• Siemens
• Mevion Medical Systems, Inc
• Varian Medical Systems, Inc
• Accuray Incorporated
• Panacea Medical Technologies Pvt. Ltd
• Pronova Solutions, LLC
• RaySearch Laboratories
• Covidien Ltd
• R. Bard, Inc
• Elekta AB
• IBA (Ion Beam Applications SA)
• P-Cure Ltd
• ViewRay Inc

Top Two Companies

• Varian Medical Systems and Elekta AB lead Radiotherapy Market Share globally, each supplying more than 20 % of new installations across major markets in recent years.

Investment Analysis and Opportunities

Investment in the Radiotherapy Market has surged as oncology infrastructure expands. In the past five years, more than 120 new radiotherapy center projects have secured capital funding globally. Venture and growth equity firms have invested over USD 500 million in radiotherapy device and software startups in that period. Proton therapy facility financing remains a flagship segment: more than 40 new proton projects are under financing or planning, each costing $40–60 million to construct. Investors see opportunity in modular linac systems: several startups received seed or Series A funding exceeding USD 10 million to build compact, lower-cost radiation systems. In developing markets, public–private partnerships (PPPs) are funding at least 30 new radiation therapy centers across Africa, Southeast Asia, and Latin America. Investment is also flowing into AI and software: more than 50 companies globally now dedicate at least 15 % of R&D budget to AI-guided Radiotherapy Market Optimization software, contouring, and adaptive planning modules.

New Product Development

Innovation in the Radiotherapy Market is accelerating with new generation systems. In 2023–2025, more than 25 MR-Linac units (combining magnetic resonance imaging with linear accelerator) were commissioned globally. Vendors introduced next-gen adaptive radiotherapy devices that adjust dose delivery mid-treatment in response to anatomical shifts. More than 15 companies unveiled AI-driven auto-contouring modules that reduce planning times by 50 %. Proton beam systems with pencil beam scanning and intensity modulated proton therapy were enhanced in over 10 installations to support complex tumors. Compact linac models with lower power and size—suitable for roadside clinics—are being prototyped; at least 5 such units are under field evaluation. Some devices now integrate surface guidance systems using optical sensors, deployed in over 120 radiotherapy centers. Intraoperative radiotherapy (IORT) devices improved dose delivery control: in 2024, ~20 hospitals added IORT suites. 

Five Recent Developments

• In 2024, Varian (a major vendor) unveiled an upgraded MR-Linac system featuring enhanced adaptive treatment capabilities that improved soft tissue targeting across 5 tumor sites.
• In 2025, Elekta expanded its Infinity / Unity line by integrating AI-driven daily adaptive planning modules in more than 10 centers.
• Mevion Medical Systems launched a next-generation compact proton therapy unit in 2024, reducing footprint by 30 % versus prior models, attracting adoption in medium hospitals.
• In late 2024, ViewRay installed a hybrid MR-Linac upgrade incorporating real-time imaging in at least 5 international treatment centers.
• In 2023, IBA (Ion Beam Applications) secured clearance for new dosimetry and beam monitoring software updates adopted by 15 proton facilities to enhance precision and safety.

Report Coverage of Radiotherapy Market

The Radiotherapy Market Report scope spans detailed quantitative and qualitative analysis across types, applications, regional breakdowns, competition, trends, and outlook. It includes segmentation by type (external beam, internal beam, systemic, others) and application (hospitals, research institutes, ambulatory centers, others), with procedure volumes, installation counts, and utilization metrics. The Radiotherapy Market Research section offers competitive landscape profiles, capturing market share by vendor, new installations, and technology leadership. The Market Insights component reviews trend analysis such as AI adoption rates, adaptive therapy uptake, proton therapy expansion, and retrofit cycles. The Market Forecast element projects installation counts, procedure volumes, and regional share shifts over a 10- to 15-year horizon (excluding revenue or CAGR narrative). Additional sections cover investment flows, new product development, recent industry developments, risk analysis (workforce, cost, regulation), and strategic buyer guidance for B2B decision makers. The report typically includes over 100 case studies, 50 technology profiles, and comprehensive maps of over 100 countries, making it a robust Radiotherapy

Radiotherapy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7403.96 Million in 2026
Market Size Value By	USD 10304.8 Million by 2035
Growth Rate	CAGR of 3.74% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : External Beam Radiotherapy Internal Beam Radiotherapy Systemic Radiotherapy Others By Application : Hospitals Cancer Research Institutes Ambulatory & Radiotherapy Centers Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample